News

green ribbon

Northern Ireland start-up Overwatch Research acquired by US giant Benchling

Congratulations to Overwatch Research, and their co-founders Chris ArmstrongGraham Wilsdon & Paul Wilsdon, on being acquired by 'US giant', Benchling.

(Pictured above from left, Overwatch Research co-founders Graham Wilsdon, Chris Armstrong and Paul Wilsdon)

In addition, congratulations to local HBAN (Halo Business Angel Network) investors, who invested in the company following its pitch to the HBAN (Halo Business Angel Network) network in November 2019.

A Northern Ireland biotech start-up has been acquired by US business Benchling.

Their software has already drawn multi-million pound export deals in the US.

Clients include Boston-based Blueprint Medicines, The Institute of Cancer Research in London and a global pharmaceutical company which agreed a multi-year seven-figure licence deal.

Dr Chris Armstrong, chief executive and co-founder, said: “Our software tackles core challenges contributing to the preclinical reproducibility crisis.

"This helps biopharmaceutical companies and contract research organizations (CROs) reduce errors, increase confidence for first-in-human studies, and ultimately get drugs to patients faster.

“By incorporating our in vivo study capabilities into Benchling’s industry-leading R&D Cloud, we’ll be able to reach more scientists and help them turn initial research findings into life-saving products.”

Sajith Wickramasekara, CEO and co-founder of Benchling, said: “Overwatch impressed us with their ability to build the first truly modern product for in vivo studies that is beloved by its customers.

It participated in the Co-Founders programme run by Catalyst NI before joining Invest NI’s Propel Pre-accelerator in 2018.

The R&D support had been part-financed by the European Regional Development Fund, which is no longer available.